Home > Publications > Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma.

Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma.

Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP and Ribas A.

New England Journal of Medicine. 369(2):134-144 2013.

Date: 2013